VJHemOnc is committed to improving our service to you

MDS 2020 | MDS: what’s the impact of early diagnosis?

VJHemOnc is committed to improving our service to you

David Steensma

David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses myelodysplastic syndromes (MDS) diagnostic patterns, early versus later diagnosis and the impact on patient outcomes. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter